Endometrial cancer and hormone-replacement therapy in the Million Women Study
Endometrial cancer and hormone-replacement therapy in the Million Women Study
复制标题
DOI：
10.1016/s0140-6736(05)66455-0
复制
发表时间：
2005-04-30
期刊：
影响因子：
168.9
通讯作者：
Reeves, G
中科院分区：
文献类型：
--
作者：
Beral, V;Bull, D;Reeves, G
绝经后妇女使用含有雌激素的激素替代疗法（HRT）会增加患子宫内膜癌的风险。为了最大限度地减少这种风险，许多没有做过子宫切除术的HRT使用者使用联合雌激素-孕激素制剂或替勃龙。有限的信息是可利用的子宫内膜癌的发病率在用户的these therapeutic.Methods 716 738绝经后妇女在英国没有以前的癌症或以前的子宫切除术被招募到百万妇女研究在1996-2001年，提供有关他们使用HRT和其他个人资料的信息，并随访了平均3.4年，结果320953名妇女（45%）在招募时报告说，她们曾使用HRT，其中69577人（22%）最后一次使用连续联合治疗（孕激素每日添加到雌激素），145 486（45%）最后一次使用周期性联合治疗（孕激素加雌激素，通常每月10-14天），28 028（9%）最后使用的替勃龙，和14 204（4%）最后使用雌激素单HRT。这些HRT类型对子宫内膜癌的总体风险有明显的对比效应（p
Background Postmenopausal women who use hormone-replacement therapy (HRT) containing oestrogen alone are at increased risk of endometrial cancer. To minimise this risk, many HRT users who have not had a hysterectomy use combined oestrogen-progestagen preparations or tibolone. Limited information is available on the incidence of endometrial cancer in users of these therapies.Methods 716 738 postmenopausal women in the UK without previous cancer or previous hysterectomy were recruited into the Million Women Study in 1996-2001, provided information about their use of HRT and other personal details, and were followed up for an average of 3.4 years, during which time 1320 incident endometrial cancers were diagnosed.Findings 320 953 women (45%) reported at recruitment that they had used HRT, among whom 69 577 (22%) last used continuous combined therapy (progestagen added daily to oestrogen), 145 486 (45%) last used cyclic combined therapy (progestagen added to oestrogen, usually for 10-14 days per month), 28 028 (9%) last used tibolone, and 14 204 (4%) last used oestrogen-only HRT. These HRT types had sharply contrasting effects on the overall risk of endometrial cancer (p